TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05540860
Drug: Sevasemten Dose 3
Normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevasemten is administered orally once per day
Study: NCT05540860
Drug: Sevasemten Dose 4
Normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevasemten is administered orally once per day
Study: NCT05540860
Drug: Sevasemten Dose 5
Normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevasemten is administered orally once per day
Study: NCT06262932
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Assess the effectiveness of repeated bolus dosing strategies of amiodarone.
Study: NCT06789705
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA will be administered in a single dose of 50 mg (2 capsules of 25 mg MDMA) or 25mg (1 capsule of 25 mg MDMA, 1 capsule containing only mannitol filler) and given at treatment visit.
Study: NCT05440942
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib will be administered orally once daily via tablet.
Study: NCT05440942
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib will be administered orally twice daily (BID) via tablet.
Study: NCT05440942
Drug: Retifanlimab
Normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retifanlimab will be administered intravenously (IV) on Day 8 of a 28-day cycle..
Study: NCT03560583
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide 10 mg BID
Study: NCT05449132
Drug: RTX-GRT7039
Normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTX-GRT7039 intra-articular injection.
Study: NCT06496620
Drug: Biological: Solrikitug high dose
DrugBank: Solrikitug (DB19301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solrikitug subcutaneous injection
Study: NCT05398029
Drug: VERVE-101
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion.
Study: NCT05050942
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
Study: NCT05050942
Drug: Lanreotide ATG
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
Study: NCT06325618
Drug: Indocyanine green (ICG)
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green will be injected to evaluate the lymphatic system.
Study: NCT05068791
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.36 mg/kg will be administered orally to participants
Study: NCT05068791
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.6 mg/kg of active placebo will be administered orally to participants
Study: NCT06100900
Drug: BCX10013
Normalized name: BCX10013
DrugBank: BCX10013 (DB18496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose levels may be tested in this study.
Study: NCT05670106
Drug: 68Ga-PSMA-11
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
Study: NCT04893629
Drug: Digoxin+furosemide+captopril
Normalized name: Captopril
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: classical heart failure medical treatment
Study: NCT05738148
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin group Vasopressin will be via umbilical vein catheter (0.4 IU/kg per dose - first line) or alternatively via an endotracheal tube (8 IU/kg) every three to five minutes as needed with a maximum of two doses if there is no ROSC \[2,3\] After that, the clinical team must convert to give epinephrine (0.02 mg/kg per dose) as long as CPR is ongoing.
Study: NCT06218888
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg，D1, Q3W
Study: NCT06218888
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 3mg ,D1-D14, Q3W
Study: NCT06218888
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide 30mg
Study: NCT05210764
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia is induced and maintained mainly with propofol.
Study: NCT05210764
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia is induced and maintained mainly with sevoflurane.
Study: NCT05210764
Drug: S-ketamine
Normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
Study: NCT05249777
Drug: TD0069 hard capsule
Normalized name: Fat, hard
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.
Study: NCT05762419
Drug: Etoposide; Oral, 50 Mg
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive focused ultrasound sonication followed by once daily oral etoposide (50mg/m\^2/dose). Oral etoposide will be taken every day for 21 days, followed by one week of rest. For the first cycle, etoposide will be administered immediately following confirming of the blood brain barrier opening through contrast magnetic resonance imaging (MRI) which will occur within 4 hours of the focused ultrasound procedure. For subsequent cycles, etoposide will be administered immediately following the focused ultrasound procedure. Subjects may continue for a maximum of 4 cycles.
Study: NCT05140122
Drug: Multiple
Normalized name: multiple vitamins
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will collect information on all medications taken by the caregiver and the person they care for.
Study: NCT04752020
Drug: Netarsudil Ophthalmic
Normalized name: netarsudil ophthalmic
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Use of netarsudil after Descemetorhexis without endothelial keratoplasty
Study: NCT05888207
Drug: Savolitinib
Normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
Study: NCT04802967
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg
Study: NCT06581003
Drug: Oxygen 99.7 %
Normalized name: oxygen 99.7 %
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group will undergo HBOT in a specialized chamber at a pressure of 2.0 ATA. Oxygen will be delivered at 100% for 60 minutes.
Study: NCT06581003
Drug: Oxygen 21 %
Normalized name: oxygen 21 %
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group will be placed in the same specialized chamber, but pressure will be 1.0 ATA (normobaric), and oxygen will be delivered at 21% (normal oxygen concentration in room air) for 60 minutes.
Study: NCT04743141
Drug: Rimegepant (PF-07899801)
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimegepant 75 mg, 50 mg or 35 mg ODT
Study: NCT06125522
Drug: vepdegestrant
Normalized name: Vepdegestrant
DrugBank: Vepdegestrant (DB19006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
Study: NCT06125522
Drug: Samuraciclib
Normalized name: Samuraciclib
DrugBank: Samuraciclib (DB16061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
Study: NCT05888207
Drug: Fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
Study: NCT05081609
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered as an intravenous (IV) infusion
Study: NCT05081609
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC chemotherapy will be administered as an intravenous (IV) infusion
Study: NCT05081609
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab will be administered as an intravenous (IV) infusion
Study: NCT05081609
Drug: Trastuzumab emtansine (T-DM1)
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine (T-DM1) will be administered as an intravenous (IV) infusion
Study: NCT04828486
Drug: Futibatinib
Normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06321289
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fludarabine 30-50 mg/m\^2/day on days -5, -4, and -3.
Study: NCT05092958
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05092958
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06068543
Drug: Epigallocatechin-3-Gallate (EGCG)
Normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg Epigallocatechin-3-Gallate (EGCG)
Study: NCT06068543
Drug: Microcrystalline cellulose (MCC)
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg microcrystalline cellulose (MCC)
Study: NCT06304545
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab IV 200mg
Study: NCT06186401
Drug: Fludarabine (non-investigational)
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06352398
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before the operation, 0.25% bupivacaine 30 ml was administered to both groups.
Study: NCT06048614
Drug: Glycerin Suppository
Normalized name: Leader Pediatric Glycerin Suppository
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned.
Study: NCT05016076
Drug: Dexamethasone 8 mg
Normalized name: dexamethasone 8 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia.
Study: NCT06056297
Drug: Mavorixafor
Normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavorixafor will be administered per schedule specified in the arm description.
Study: NCT06340854
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Icodec will be administered subcutaneously.
Study: NCT06340854
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine will be administered subcutaneously.
Study: NCT06237881
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06237881
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06687369
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2 IV, every 3 weeks on Day 1
Study: NCT06687369
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Area under the curve (AUC) 5 IV, every 3 weeks on Day 1 for 4 cycles.
Study: NCT06687369
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 IV, every 3 weeks on Day 1 for 4 cycles
Study: NCT04654468
Drug: Crovalimab
Normalized name: Crovalimab
DrugBank: Crovalimab (DB16128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight \>=100kg). Dosing schedule will be as described above.
Study: NCT05474560
Drug: Allopurinol (100 mg/day) plus lifestyle intervention
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Study: NCT05474560
Drug: Febuxostat 40 mg plus lifestyle intervention
Normalized name: febuxostat 40 MG
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Study: NCT06508658
Drug: Epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT06508658
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) Infusion
Study: NCT06508658
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Capsule
Study: NCT06508658
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Infusion
Study: NCT06508658
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Infusion
Study: NCT05165524
Drug: Triple cream
Normalized name: Triple Cream
DrugBank: Atriplex wrightii pollen (DB10391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with a triple brightening cream (Pigmanorm®), applied daily, three times per week for 12 weeks on the lesion. Interruption for 4 days will be adopted in case of irritation/redness. 50+ sun protection cream will be used as well during the treatment period.
Study: NCT05459688
Drug: CIN-107
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg of CIN-107, once a day for 52 weeks
Study: NCT05944224
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, 6mg/Kg,28 days/cycle
Study: NCT05882071
Drug: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
Study: NCT05568706
Drug: EDP-938
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take EDP-938 once daily for 5 days
Study: NCT06217185
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 400mg qd po continuously
Study: NCT06217185
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For Trastuzumab, the loading dose for the first treatment cycle is 8 mg/kg, and for subsequent cycles, 6 mg/kg. It is to be used once every three weeks
Study: NCT06269484
Drug: Zibotentan + placebo (placebo matching dapagliflozin tablet)
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: zibotentan capsule~placebo tablet (matching dapagliflozin tablet)
Study: NCT06269484
Drug: Zibotentan + dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: zibotentan capsule~dapagliflozin 10 mg tablet
Study: NCT04655755
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05053503
Drug: Lofexidine
Normalized name: LOFEXIDINE
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
Study: NCT05053503
Drug: Extended-release injectable naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.
Study: NCT06577987
Drug: CID-078 Monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclin A/B-RxL inhibitor, twice-a-day in repeating 21-day treatment cycles until disease progression or discontinuation criteria.
Study: NCT04975308
Drug: Imlunestrant
Normalized name: Imlunestrant
DrugBank: Imlunestrant (DB19043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04975308
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04975308
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered IM.
Study: NCT04975308
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT05740813
Drug: ABBV-CLS-7262 Dose 1
Normalized name: Calf lung surfactant extract (CLSE)
DrugBank: ABBV-CLS-7262 (DB18407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-CLS-7262 is administered orally once per day for 24 weeks.
Study: NCT05740813
Drug: ABBV-CLS-7262 Dose 2
Normalized name: Calf lung surfactant extract (CLSE)
DrugBank: ABBV-CLS-7262 (DB18407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-CLS-7262 is administered orally once per day for 24 weeks.
Study: NCT04298203
Drug: Phentermine-Topiramate
Normalized name: phentermine-topiramate
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study medication to be tested for this study is a combination of phentermine and topiramate.
Study: NCT05952037
Drug: BGB-11417
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a tablet.
Study: NCT05952037
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally as a tablet.
Study: NCT06045221
Drug: Orforglipron
Normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06045221
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT05348876
Drug: Darolutamide (Nubeqa, BAY1841788)
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
Study: NCT06331728
Drug: IGNX001
DrugBank: NX001 (DB18099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGNX001 given as a single subcutaneous dose on Day 1.
Study: NCT06136988
Drug: Docetaxel for Injection (Albumin-bound)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W
Study: NCT06136988
Drug: SG001
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W
Study: NCT06136988
Drug: Cisplatin for injection
Normalized name: Cisplatin for Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W